HPV Country Profile

Statistics and Data Analytics


cases in 2018



deaths in 2018

Status of National HPV Vaccination Programme

The HPV vaccine is currently not included in Turkey’s national immunization program.


General Information

Human Papillomavirus

Burden of HPV infection

In Turkey, about 4.7% of women in the general population are estimated to have HPV type 16 or 18 at a given time, which causes approximately 76.0% of invasive cervical cancers in the country. Approximately 25% of women have any type of HPV, according to a 2013 study.1,4

Burden of cervical cancer

Cervical cancer, caused by HPV, is the fifteenth leading cause of cancer deaths in women in Turkey, causing at least 1280 deaths annually among the population of 31.1 million women aged 15 years and older who are at risk for the disease.1,2 Between 2012 and 2018, the number of deaths every year due to cervical cancer nearly doubled (663 in 2012 to 1280 in 2018), and if decisive action is not taken at the national level, annual deaths due to the disease will nearly double again by 2040, reaching 2210 deaths per year.3 In Turkey, at least 2356 women are newly diagnosed with cervical cancer each year.

4.8 per 100,000 women in Turkey contract cervical cancer annually and 2.5 per 100,000 women die due to the disease each year in Turkey. Compared to countries in the MENA region (as defined by UNAIDS), Turkey’s death and incidence rates due to cervical cancer are relatively low. For example, Somalia and Morocco have the highest incidence and mortality rates, with 24.0 and 17.2 women per 100,000 being newly diagnosed with cervical cancer annually and at least 21.9 and 12.6 women per 100,000 dying due to cervical cancer per year, respectively. Whereas Iran, Iraq and Yemen have the lowest (around 2 per 100,000 women are diagnosed per year and about 1 per 100,000 die because of cervical cancer annually).2

Cervical cancer incidence and mortality rate projections
Research and Publications
  1. Tuncer, Hasan Aykut. “Women’s Knowledge, Awareness and Attitudes toward Newly Implemented National HPV-Based Screening in Turkey.” Journal of Cancer Policy, Nov. 2019, p. 100205, doi:10.1016/j.jcpo.2019.100205.
  2. Moore, K., et al. “992OFORWARD I (GOG 3011): A Phase III Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRa)-Targeting Antibody-Drug Conjugate (ADC), versus Chemotherapy in Patients (Pts) with Platinum-Resistant Ovarian Cancer (PROC).” Annals of Oncology, vol. 30, no. Supplement_5, Oct. 2019, p. mdz250, doi:10.1093/annonc/mdz250.
  3. Başer, Emre, et al. “Awareness of Women about Cervical Smear, Human Papilloma Virus and Human Papilloma Virus Vaccine.” Human Papilloma Virus, Sept. 2019, p. 6.
  4. Baş, Yılmaz, et al. “Effect of High Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma in Somalian and Turkish Cases.” Pathogens and Disease, Aug. 2019, doi:10.1093/femspd/ftz047.
  5. Erenoğlu, Rabiye, and Şengül Yaman Sözbir. “The Effect of Health Education Given to Syrian Refugee Women in Their Own Language on Awareness of Breast and Cervical Cancer, in Turkey: A Randomized Controlled Trial.” Journal of Cancer Education, Aug. 2019, doi:10.1007/s13187-019-01604-4.
  6. Özdemir, Serpil, et al. “Analysis of Community-Based Researches Related to Knowledge, Awareness, Attitude and Behaviors towards HPV and HPV Vaccine Published in Turkey: A Systematic Review.” Journal of the Turkish German Gynecological Association, Aug. 2019, doi:10.4274/jtgga.galenos.2019.2019.0071.
  7. Aynaci, Gulden, and Zuhal Gusku. “Awareness of HPV and HPV Vaccination in Undergraduate Students in the North West Region of Turkey: Near Future Outlook.” The Journal of Infection in Developing Countries, vol. 13, no. 06, June 2019, pp. 516–25, doi:10.3855/jidc.11405.
  8. Gultekin, Murat, et al. “Mega Hpv Laboratories for Cervical Cancer Control: Challenges and Recommendations from a Case Study of Turkey.” Papillomavirus Research, vol. 7, June 2019, pp. 118–22, doi:10.1016/j.pvr.2019.03.002.
  9. Kilic, Ayse, et al. “Breast and Cervical Cancer Screening for Women with Physical Disabilities: A Qualitative Study of Experiences and Barriers.” Journal of Advanced Nursing, vol. 0, no. ja, May 2019, doi:10.1111/jan.14048.
  10. Sarier, Mehmet, et al. “Is There Any Association between Urothelial Carcinoma of the Bladder and Human Papillomavirus? A Case-Control Study.” Urologia Internationalis, May 2019, pp. 1–6, doi:10.1159/000500467.
  11. Findik, Siddika, et al. Human Papillomavirus (HPV) Subtypes and Their Relationships with Cervical Smear Results in Cervical Cancer Screening: A Community-Based Study from the Central Anatolia Region of Turkey. Apr. 2019, p. 8.
  12. Kaleli, İ., et al. “[Prevalence and genotype distribution of human papillomavirus in patients attending to gynecology polyclinics].” Mikrobiyoloji bulteni, vol. 53, no. 2, Apr. 2019, pp. 170–78, doi:10.5578/mb.67765.
  13. Kurt, Gonul, and Aygul Akyuz. “Evaluating the Effectiveness of Interventions on Increasing Participation in Cervical Cancer Screening.” The Journal of Nursing Research: JNR, Mar. 2019, doi:10.1097/jnr.0000000000000317.
  14. Korkut, Yasemin. “Assessment of Knowledge, Attitudes, and Behaviors Regarding Breast and Cervical Cancer among Women in Western Turkey.” Journal of International Medical Research, Mar. 2019, p. 030006051983025, doi:10.1177/0300060519830252.
  15. Cift, Tayfur, et al. “Assessment of Knowledge and Attitudes of Midwives and Nurses Working at the Hospital about HPV Infection and Vaccinations.” European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 234, Mar. 2019, p. e176, doi:10.1016/j.ejogrb.2018.08.546.
View all publications
  1. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Turkey. Summary Report 27 July 2017. [19 October, 2018]

  2. Cancer Today. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  3. Cancer Tomorrow. (2018, September). Retrieved October 19, 2018, from https://gco.iarc.fr/.

  4. Dursun et al. (2013). HPV Types in Turkey: Multicenter Hospital Based Evaluation of 6388 Patients in Turkish Gynecologic Oncology Group Centers / Türkiye’deki HPV Tipleri: Türk Jinekolojik Onkoloji Grubuna Üye Merkezlere Başvuran 6388 Hastanın Retrospektif Analizi, Turkish Journal of Pathology, 29(3), 210-216. doi: https://doi.org/10.5146/tjpath.2013.01188

Please notify us if you know of other resources, including academic publications, news articles and information that should be added to this page by emailing: hpvmena@gmail.com.